Researchers in white lab coats reviewing a computer display beside a microscope.

PDE2 Drug Program Builds on FRAXA-Funded Research

October 28, 2026

A PDE2 drug program for Fragile X syndrome builds on FRAXA-funded research as Rumi Therapeutics advances RTX-7340 toward clinical development.

Read More »
Dr. Thomas Maurin and Dr. Barbara Bardoni, Fragile X researchers and co-authors of a 2025 review on PDE inhibitors published in Cell Reports Medicine.

Fragile X and PDE Inhibitors: A Promising Path Forward for Brain Disorders

March 26, 2025

Fragile X syndrome research shows PDE inhibitors may improve brain function and behavior, with promise for related neurodevelopmental disorders.

Read More »
Dr. Thomas Maurin and Dr. Barbara Bardoni, Fragile X researchers and co-authors of a 2025 review on PDE inhibitors published in Cell Reports Medicine.

Research Points to Drugs which Inhibit PDE to Treat Fragile X

November 4, 2018

FRAXA-funded work identified PDE enzymes as key targets in Fragile X, showing that PDE inhibitors can fix signaling and boost synaptic function. PDE4D trials are underway.

Read More »

Brain Revolution: French Scientists Bardoni and Maurin Study FMRP

July 5, 2016

Bardoni and Maurin study how FMRP interacts with other molecules in the brain, identifying targets and signaling pathways that could lead to new drug therapies for Fragile X.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (42)